[1] WHO. Tuberculosis. November 2010. http://www.who.int/mediacentre/factsheets/fs104/en/
[2] Dye, C., Williams, B., Espinal, M. and Raviglion, M. (2002) Erasing the world’s slow stain: Strategies to beat multidrug-resistant tuberculosis. Science, 295, 2042- 2046. doi:10.1126/science.1063814
[3] Morris, S., Bai, G., Suffys, P., Portilo, L., Fairchok, M. and Rouse, D. (1995) Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis. Infectious Diseases, 171, 954-960. doi:10.1093/infdis/171.4.954
[4] Telzak, E., Sepkowitz, K., Alpert, P., Mannheimer, S., Mederd, F., El-Sadr, W., Blum, S., Gagliardi, A., Alomon, N. and Turett, G. (1995) Multidrug-Resistant Tuberculosis in Patients without HIV Infection. The New England Journal of Medicineogy, 333, 907-912. doi:10.1056/NEJM199510053331404
[5] Basso, L. and Blanchard, J. S. (1998) Resistance to anti-tubercular drugs. Advances in Experimental Medicine and Biology, 456, 115-144. doi:10.1007/978-1-4615-4897-3_7
[6] Navarrete-Vázquez, G., Molina-Salinas, G., Duarte- Fa-jardo Zetel, Z., Villarrea, J., Estrada-Soto, S., González- Salazar, F., Hernández-Nú?ez, E., Fernendez, S. S. (2007) Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines. Bioorganic & Me- dicinal Chemistry, 5, 5502-5508. doi:10.1016/j.bmc.2007.05.053
[7] Shaban, M.A.E., Nasr, A.Z. and El-Badry, J. (1991) Syn-thesis and biological activities of some 1, 3, 4-oxadiazoles and bis (1, 3, 4-oxadiazoles). Journal of Islamic Academy of Sciences, 143, 184-186.
[8] Karakus, S. and Rollas, S. (2002) Synthesis and antitu-berculosis activity of new N-phenyl-N′-[4-(5-alkyl/ arylamino-1,3,4-thiadiazole-2-yl)phenyl]thioureas. Far-maco, 57, 577-581. doi:10.1016/S0014-827X(02)01252-1
[9] Oruc, E., Rollas, S., Kandemirli, F., Shvets, N., Dimoglo, A. (2004) 1,3,4-Thiadiazole Derivatives. Synthesis, Structure Elucidation, and Structure?Antituberculosis Activity Relationship Investigation. Journal of Medicinal Chemistry, 47, 6760-6767.
[10] Nilufer, S., Sevim, R. (2006) Synthesis and antitubercu-losis activity of 2-(aryl/alkylamino)-5-(4-aminophenyl)- 1,3,4-thiadiazoles and their Schiff bases. Arkivoc, 12, 173-181.
[11] Macaev, F., Ghenadie, R., Serghei, P., Alexandru, G., Eugenia, S., Ludmila, V., Nathaly, S., Fatma, K., Anatholy, D. and Robert, R. (2005) Synthesis of novel 5-aryl-2-thio-1,3,4-oxadiazoles and the study of their structure—anti-mycobacterial activities. Bioorganic & Medicinal Chemistry, 13, 4842-4850. doi:10.1016/j.bmc.2005.05.011
[12] Wilder-Smith, A.E. (1966) Some recently synthesised tuberculostatic 4-substituted oxadiazolones and oxadiazol- thiones. Arzneimittelforschung, 16, 1034-1038.
[13] Mamolo, M., Zampieri, D., Vio, L., Fermeglia, M., Fer-rone, M., Pricl, S., Scialino, G. and Banfi, E. (2005) An-timycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations. Bioorganic & Medicinal Chemistry, 13, 3797-3809. doi:10.1016/j.bmc.2005.03.013
[14] Ali, M.S. and Shaharya, M. (2007) Oxadiazole mannich bases: Synthesis and antimycobacterial activity. Bio- organic & Medicinal Chemistry Letters, 17, 3314- 3316. doi:10.1016/j.bmcl.2007.04.004
[15] a) Foroumadi, A., Kiani, Z., Soltani, F. (2003) Antitu-berculosis agents VIII: Synthesis and in vitro antimyco-bacterial activity of alkylα-[5-(5-nitro-2-thienyl)-1,3,4- thiadiazole-2-ylthio]acetates. Farmaco, 58, 1073-1076. doi:10.1016/S0014-827X(03)00158-7 b)Foroumadi, A., Sakhteman, A., Sharifzadeh, Z., Mohammad, H., Hem-mateenejad, B., Moshafi, M., Vosooghi, M., Amini, M.K. and Shafiee, A. (2007) Synthesis,
[16] antituberculosis activity and QSAR study of some novel 2-(nitroaryl)- 5-(nitrobenzylsulfinyl and sulfonyl)-1,3,4-thiadiazole de-rivatives. DARU Journal of Pharmaceutical Sciences, 15, 218-226.
[17] Foroumadi, A., Zahra, K. (2006) Synthesis and antimy-cobacterial activity of some alkyl [5-(nitroaryl)-1,3,4- thiadiazol-2-ylthio]propionates. Bioorganic & Medicinal Chemistry Letters, 16, 1164-1167. doi:10.1016/j.bmcl.2005.11.087
[18] Karthikeyan, M., Prasad, D.J., Boja, P., Bhat, S., Bantwal, S. and Nalilu, S. (2006) Synthesis and biological activity of Schiff and Mannich bases bearing 2,4-dichloro- 5-fluorophenyl moiety. Bioorganic & Medicinal Che- mistry, 14, 7482-7489. doi:10.1016/j.bmc.2006.07.015
[19] Raparti, V., Chitre, T., Bothara, K.G., Kumar, V., Dangre, S., Khachane, C., Gore, S., Deshmane, B. (2009) Novel 4-(morpholin-4-yl)-N′-(arylidene)benzohydrazides: Syn-thesis, antimycobacterial activity and QSAR invest- tiga-tions. European Journal of Medicinal Chemistry, 44, 3954-3960. doi:10.1016/j.ejmech.2009.04.023
[20] Sriram, D., Yogeeswari, P. and Reddy, S. (2008) Anti-mycobacterial activities of novel 2-(sub)-3-fluoro/nitro- 5,12-dihydro-5-oxobenzothizolo[3,2-a]quinoline-6-carboxylic acid. Bioorganic & Medicinal Chemistry, 16, 3408- 3418. doi:10.1016/j.bmc.2007.11.016
[21] Joshi, S. and Khosla, N. (2004) In vitro study of some medicinally important Mannich bases derived from anti-tubercular agent. Bioorganic & Medicinal Chemistry, 12, 571-576. doi:10.1016/j.bmc.2003.11.001
[22] Singh, I.P., Saxena, A.K., Shankar, K. (1986) Synthesis and anti-inflammatory activity of oxadiazoline thione hydrochlorides. European Journal of Medicinal Che- mi-stry: Chimica Therapeutica, 21, 267-269.
[23] Jorgensen, W., Maxwell, D., Tirado-Rives, J. (1996) Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. Journal of American Chemical Society, 118, 11225-11236. doi:10.1021/ja9621760
[24] Podust, L., Poulos, T., Waterman, M. (2001) Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proceedings of the National Aca- demy of Sciences of U.S.A, 98, 3068-3073. doi:10.1073/pnas.061562898
[25] Hayes, M. J., Stein, M. and Weiser, J. (2004) Accurate Calculations of Ligand Binding Free Energies: Chiral Separation with Enantioselective Receptors. The Journal of Physical Chemistry, 108, 3572-3580.
[26] Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. (2006) Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein?Ligand Complexes. Journal of Medicinal Chemistry, 49, 6177. doi:10.1021/jm051256o
[27] Elmer, W.K., Stephen, D.A., William, M.J., Paul, C.S. and Washing, C.W. (2002) Text book of Diagnostic Mi-crobiology 5 Lippincot-Pub, J. B. Lippincott Co., Phila-delphia, p. 125.
[28] Goto, S., Jo, K., Kawakita, T., Kosakai, N., Mitsuhashi, S., Nishino, T., Ohsawa, N., Tanami, H. (1981) Determi- nation method of minimum inhibitory concentrations. Chemotherapy, 29, 76-79.